Generation of Stable cisPt Resistant Lung Adenocarcinoma Cells

Generation of Stable cisPt Resistant Lung Adenocarcinoma Cells

Platinum compounds represent the backbone of combined chemotherapy protocols for advanced lung cancer. The mechanisms responsible for its frequent primary or acquired resistance to cisplatin (cisPt)-based chemotherapy remains enigmatic. The availability of two cell lines of the same origin, one resi...

Full description

Bibliographic Details
Main Authors:	Nico Ruprecht, Lukas Hofmann, Martin Nils Hungerbühler, Christoph Kempf, Johannes Thomas Heverhagen, Hendrik von Tengg-Kobligk
Format:	Article
Language:	English
Published:	MDPI AG 2020-05-01
Series:	Pharmaceuticals
Subjects:	cisplatin NSCLC lung cancer VRAC resistance
Online Access:	https://www.mdpi.com/1424-8247/13/6/109

Similar Items

Beyond Single-Cell Analysis of Metallodrugs by ICP-MS: Targeting Cellular Substructures
by: Audrey Galé, et al.
Published: (2021-08-01)

The Volume-Regulated Anion Channel in Glioblastoma
by: Martino Caramia, et al.
Published: (2019-03-01)

Knockdown of Long Non-Coding RNA HOTAIR Suppresses Cisplatin Resistance, Cell Proliferation, Migration and Invasion of DDP-Resistant NSCLC Cells by Targeting miR-149-5p/Doublecortin-Like Kinase 1 Axis
by: Zhan Y, et al.
Published: (2020-08-01)

Comparison of Chemotherapy Regiments between Cisplatin Etoposide and Cisplatin-Docetaxel on 2-Year and Progression-Free Survival in Late-Stage Non-Small Cell Lung Cancer Patients
by: Salman Paris Harahap, et al.
Published: (2016-06-01)

SWELL1 regulates skeletal muscle cell size, intracellular signaling, adiposity and glucose metabolism
by: Ashutosh Kumar, et al.
Published: (2020-09-01)

Efficacy and Toxicity of Pemetrexed or Gemcitabine Combined with Cisplatin in the Treatment of Patients with Advanced Non-small Cell Lung Cancer
by: Xingsheng HU, et al.
Published: (2012-10-01)

Scutellarin Increases Cisplatin-Induced Apoptosis and Autophagy to Overcome Cisplatin Resistance in Non-small Cell Lung Cancer via ERK/p53 and c-met/AKT Signaling Pathways
by: Chao-Yue Sun, et al.
Published: (2018-02-01)

Turning down the volume: Astrocyte volume change in the generation and termination of epileptic seizures
by: Thomas R. Murphy, et al.
Published: (2017-08-01)

VI-116, A Novel Potent Inhibitor of VRAC with Minimal Effect on ANO1
by: Jeon, D., et al.
Published: (2022)

Les canaux anioniques sensibles au gonflement cellulaire : inhibiteurs, perméabilité, rôle dans la transition épithéliomésenchymateuse et l’inflammasome
by: Friard, Jonas
Published: (2018)

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells
by: Jing Wang, et al.
Published: (2019-10-01)

Cordycepin Reverses Cisplatin Resistance in Non-small Cell Lung Cancer by Activating AMPK and Inhibiting AKT Signaling Pathway
by: Xiao-Zhong Liao, et al.
Published: (2021-01-01)

Phenethyl Isothiocyanate and Cisplatin Co-Encapsulated in a Liposomal Nanoparticle for Treatment of Non-Small Cell Lung Cancer
by: Mengwei Sun, et al.
Published: (2019-02-01)

Inhaled Cisplatin for NSCLC: Facts and Results
by: Christoforos Kosmidis, et al.
Published: (2019-04-01)

ATF3 as a Key Regulator of Cisplatin Cytotoxicity: Combining ATF3 Inducing Agents Enhances Cisplatin Activity in NSCLC
by: Baghai, Tabassom
Published: (2018)

Cryo-EM structures of the DCPIB-inhibited volume-regulated anion channel LRRC8A in lipid nanodiscs
by: David M Kern, et al.
Published: (2019-02-01)

Ca2+ Dependence of Volume-Regulated VRAC/LRRC8 and TMEM16A Cl– Channels
by: Raquel Centeio, et al.
Published: (2020-12-01)

LRRCA8A and ANO1 contribute to serum-induced VRAC in a Ca2+-dependent manners
by: Huiran Zhang, et al.
Published: (2020-07-01)

Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
by: Laksmi Wulandari, et al.
Published: (2021-08-01)

FUT4siRNA augments the chemosensitivity of non-small cell lung cancer to cisplatin through activation of FOXO1-induced apoptosis
by: Wei Gao, et al.
Published: (2020-09-01)

Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment
by: Yanyun Gao, et al.
Published: (2019-11-01)

miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway
by: Wei Sun, et al.
Published: (2018-12-01)

Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs
by: Mohd Farhan, et al.
Published: (2019-02-01)

Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non–small-cell lung cancer xenograft models
by: Coxon Angela, et al.
Published: (2012-09-01)

LRRC8A is essential for hypotonicity-, but not for DAMP-induced NLRP3 inflammasome activation
by: Jack P Green, et al.
Published: (2020-11-01)

TTYH1 and TTYH2 Serve as LRRC8A-Independent Volume-Regulated Anion Channels in Cancer Cells
by: Yeonju Bae, et al.
Published: (2019-06-01)

The Volume-Regulated Anion Channel LRRC8/VRAC Is Dispensable for Cell Proliferation and Migration
by: Tianbao Liu, et al.
Published: (2019-05-01)

Upstream regulators of VRAC activation in Human 1321N1 Astrocytoma Cells
by: Moore, Courtney Elyse
Published: (2017)

MiR-140 Resensitizes Cisplatin-Resistant NSCLC Cells to Cisplatin Treatment Through the SIRT1/ROS/JNK Pathway
by: Lin Z, et al.
Published: (2020-08-01)

Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin
by: Zang S, et al.
Published: (2019-09-01)

Arsenic sulfide reverses cisplatin resistance in non‐small cell lung cancer in vitro and in vivo through targeting PD‐L1
by: Wei Tian, et al.
Published: (2021-10-01)

Histone Deacetylase Inhibitor Sensitizes ERCC1-High Non-small-Cell Lung Cancer Cells to Cisplatin via Regulating miR-149
by: Yuwen He, et al.
Published: (2020-06-01)

Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy
by: Ye Tian, et al.
Published: (2018-06-01)

Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress
by: Christophe Deben, et al.
Published: (2018-04-01)

Oxymatrine and Cisplatin Synergistically Enhance Anti-tumor Immunity of CD8+ T Cells in Non-small Cell Lung Cancer
by: Jin Ye, et al.
Published: (2018-12-01)

Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene
by: Wang H, et al.
Published: (2021-04-01)

SMYD3 confers cisplatin chemoresistance of NSCLC cells in an ANKHD1-dependent manner
by: Hong-Wei Lv, et al.
Published: (2021-06-01)

Cost-effectiveness analysis of paclitaxel + carboplatin vs. alternative combinations in the treatment of non-small cell lung cancer
by: Mario Eandi
Published: (2006-09-01)

ATP Release Channels
by: Akiyuki Taruno
Published: (2018-03-01)

Anti-Tumor Effects of a Penetratin Peptide Targeting Transcription of E2F-1, 2 and 3a Is Enhanced When Used in Combination with Pemetrexed or Cisplatin
by: Gulam Mohmad Rather, et al.
Published: (2021-02-01)